Surf Wiki
Save to docs
general/combination-analgesics

From Surf Wiki (app.surf) — the open knowledge base

Oxycodone/naloxone

Combination pain relief drug

Summary

Combination pain relief drug

| Drugs.com =

Oxycodone/naloxone, sold under the brand name Targin among others, is a combination pain medication available as modified-release tablets administered by mouth.

The oxycodone component is an opioid and is responsible for the pain-relieving effects. Naloxone, an opioid antagonist, opposes the effects of opioids but is poorly absorbed into the blood stream when administered orally; therefore, most of the dose remains in the gastrointestinal tract. This local presence reduces opioid-induced constipation by preventing oxycodone from binding to gut opioid receptors, without diminishing overall analgesic efficacy compared to oxycodone alone. A 2008 study demonstrated a significant reduction in constipation. Oxycodone/naloxone was released in 2014 in the United States, in 2006 in Germany, and has been available in some other European countries since 2009. In the United Kingdom, the 10 mg oxycodone / 5 mg naloxone and 20 mg / 10 mg strengths were approved in December 2008, and the 40 mg / 20 mg and 5 mg / 10 mg strengths received approval in July 2019.

Preliminary evidence suggests that oxycodone/naloxone may be an effective treatment for severe, refractory restless legs syndrome if first-line therapies have not been effective.

Adverse effects

References

References

  1. "Public Summary". Australian Government, Department of Health and Aged Care.
  2. (28 September 2022). "Oxonal (AU Pharma Pty Ltd)".
  3. (22 October 2009). "Targin Product information".
  4. (16 March 2021). "Targinact 5 mg/2.5 mg prolonged-release tablets - Summary of Product Characteristics (SmPC)".
  5. (22 December 2016). "Targiniq ER- oxycodone hydrochloride/naloxone hydrochloride tablet, film coated, extended release".
  6. (December 2008). "Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain". Current Medical Research and Opinion.
  7. Mundipharma. (2009-01-26). "Targin (oral oxycodone/naloxone prolonged-release tablet) now launching across Europe to control severe chronic pain with significantly reduced risk of opioid-induced constipation".
  8. (2016). "Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone". Neuropsychiatric Disease and Treatment.
  9. (December 2013). "Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension". The Lancet. Neurology.
  10. (June 2016). "Opioids for restless legs syndrome". The Cochrane Database of Systematic Reviews.
Wikipedia Source

This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.

combination-analgesics semisynthetic-opioids
Want to explore this topic further?

Ask Mako anything about Oxycodone/naloxone — get instant answers, deeper analysis, and related topics.

Research with Mako

Free with your Surf account

Content sourced from Wikipedia, available under CC BY-SA 4.0.

This content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.

Report